MCA registered Company Details
InsightsCompaniesSectorsDirectorsInvestorsCompare
RegisterKaro › MCA registered Company Details

Invictus Oncology

U24232DL2011PTC217394ActivePrivateUnlisted
Last updated: 2026-06-08
30
Compliance Health · F
3 / 9 signals passed

Invictus Oncology is a Private Indian company incorporated in 2011 and based in Delhi, India. Invictus Oncology operates in Pharmaceuticals & Chemicals (NIC 24232) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.

Risk FlagsFinancials not yet extracted · awaiting AOC-4 XBRLDirectors not yet extracted · awaiting MGT-7Health F · 30/100
Revenue (latest FY)
—
Awaiting extraction
PAT (latest FY)
—
Awaiting extraction
Open Charges
0
No encumbrances
Active Directors
0
No resignations
Paid-up Capital
—
—
Filings on Record
0
All current
Incorporated
2011
15 years old
State
Delhi
Sector
Pharmaceuticals & Chemicals
NIC 24232
Class
Private
Sub-category
—
Authorized Capital
—
Paid-up Capital
—
Members
—
Last AGM
—
Last Balance Sheet
—
Latest Filing
—
Registered Email
—
Registered Office
—
Invictus OncologyTRACXN · PUBLIC DATA
Brand Invictus Oncology · Legal entity Invictus Oncology

Invictus Oncology - Developer of chemotherapeutics conjugated with antibodies for the treatment of cancer. Raised a total funding of $6.99M over 7 rounds from 21 investors.

Total Funding
Latest Round
Series A
Revenue
Valuation
Funding Rounds
—
Employees
16
Stage
Series A
HQ
Delhi
Founded
2011
Source: Tracxn (public profile) · joined to MCA on CIN U24232DL2011PTC217394

Quick facts

Identity · Activity · Auditor · Contact
Registered office
—
NIC code
24232
Statutory auditor
Awaiting ADT-1 / AOC-4 extraction
Registered email
—
Section
Pharmaceuticals & Chemicals
ROC
—
Website
http://invictusoncology.com
Class · sub-category
Private
Incorporation · Last AGM
— · —

Directors

From MGT-7 annual returnLocked
AD
Anita Desai
Director
2.0y · Mumbai · DIN 5075209
RK
Rajesh Kumar Sharma
Whole-time Director
8.5y · Chennai · DIN 2666968
SG
Sneha Gupta
Additional Director
6.1y · Bengaluru · DIN 2820702
PN
Priya Nair
Whole-time Director
3.8y · Ahmedabad · DIN 4850732
Get the full board of directors

Directors, DINs & appointment history for Invictus Oncology.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

MCA Filings

AOC-4 · MGT-7 historyLocked
FormFYFiledDueDelayStatus
AOC-4FY2024-2530 Oct 202430 Oct 20240dfiled
MGT-7FY2024-2521 Nov 202429 Nov 20240dfiled
AOC-4FY2023-2430 Oct 202330 Oct 2023+17dfiled
MGT-7FY2023-2420 Nov 202329 Nov 20230dfiled
AOC-4FY2022-2330 Oct 202230 Oct 20220dfiled
MGT-7FY2022-2326 Nov 202229 Nov 20220dfiled
Get financial statements & other filing documents

Full MCA filing history for Invictus Oncology.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

Charges

Registered charges & encumbrancesLocked
Charge IDHolderAmountCreatedStatus
608930502HDFC Bank Ltd(Bank)₹14.33 Cr27 Jan 2019Satisfied
971837554HDFC Bank Ltd(Bank)₹9.39 Cr19 Sep 2023Satisfied
299982490HDFC Bank Ltd(Bank)₹24.63 Cr04 Jul 2021Open
752930339Kotak Mahindra Bank Ltd(Bank)₹9.87 Cr27 Jan 2020Open
749992284Kotak Mahindra Bank Ltd(Bank)₹19.89 Cr19 Sep 2020Open
See registered charges & lenders

Charge IDs, lenders & amounts for Invictus Oncology.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

Financial Performance

Revenue · PAT · Net worth by FYLocked
FYRevenuePATNet WorthTotal AssetsEmployees
FY2024-25₹11.20 Cr₹-62.05 L₹5.21 Cr₹13.47 Cr39
FY2023-24₹9.15 Cr₹-29.67 L₹7.39 Cr₹10.67 Cr327
FY2022-23₹7.13 Cr₹-33.56 L₹4.28 Cr₹10.52 Cr175
FY2021-22₹9.16 Cr₹-51.08 L₹4.09 Cr₹8.75 Cr154
Gain deeper financial insights of this entity

Audited financials & ratios for Invictus Oncology.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Detailed Financials

Income statement + balance sheetLocked
Line itemFY2024-25FY2023-24FY2022-23FY2021-22
Income statement
Revenue from operations₹11.20 Cr₹9.15 Cr₹7.13 Cr₹9.16 Cr
Other income₹20.49 L₹29.15 L₹5.84 L₹36.05 L
Total income₹11.41 Cr₹9.44 Cr₹7.18 Cr₹9.52 Cr
Total expenses₹12.20 Cr₹9.82 Cr₹7.61 Cr₹10.17 Cr
Profit before tax₹-80.67 L₹-38.57 L₹-43.63 L₹-66.41 L
Profit / (Loss) after tax₹-62.05 L₹-29.67 L₹-33.56 L₹-51.08 L
Balance sheet
Equity / Net worth₹5.21 Cr₹7.39 Cr₹4.28 Cr₹4.09 Cr
Borrowings₹4.34 Cr₹1.06 Cr₹1.55 Cr₹2.14 Cr
Current liabilities₹3.28 Cr₹1.63 Cr₹2.44 Cr₹2.42 Cr
Total liabilities₹8.25 Cr₹3.28 Cr₹6.24 Cr₹4.65 Cr
Current assets₹7.21 Cr₹5.56 Cr₹6.29 Cr₹3.61 Cr
Cash & equivalents₹2.24 Cr₹1.67 Cr₹2.49 Cr₹69.72 L
Total assets₹13.47 Cr₹10.67 Cr₹10.52 Cr₹8.75 Cr
Employees39327175154
Gain deeper financial insights of this entity

Audited financials & ratios for Invictus Oncology.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Compounded Annual Growth Rate

Derived from multi-FY filingsLocked
MetricLatest value1Y CAGR3Y CAGR5Y CAGR
Revenue₹11.20 Cr-9.9%+8.1%+15.9%
Profit after Tax₹-62.05 L-7.3%+15.4%+18.9%
Net Worth₹5.21 Cr-9.0%-5.5%+3.6%
Employees39+23.8%+5.5%+8.2%
Gain deeper financial insights of this entity

Audited financials & ratios for Invictus Oncology.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Financial Ratios

Profitability · leverage · efficiencyLocked
FYRevenuePATPAT marginRev growthROEROAD/ERev/emp
FY2024-25₹11.20 Cr₹-62.05 L-5.54%+0.91%-11.91%-4.61%0.83₹28.73 L
FY2023-24₹9.15 Cr₹-29.67 L-3.24%+17.03%-4.01%-2.78%0.14₹2.80 L
FY2022-23₹7.13 Cr₹-33.56 L-4.71%+35.70%-7.84%-3.19%0.36₹4.07 L
FY2021-22₹9.16 Cr₹-51.08 L-5.58%+25.73%-12.49%-5.84%0.52₹5.95 L
Gain deeper financial insights of this entity

Audited financials & ratios for Invictus Oncology.

₹999₹249(excl. taxes)
Buy Financial Report
What you'll get
  • Financial Summary & Charts
  • Income Statement, Balance Sheet, Cashflow
  • Profitability, Liquidity & Growth Ratios
  • Audited Financial Statement (AOC-4)

Cap Table & Shareholding

Promoter · institutional · publicLocked
CategoryShareholdersShares held%
Promoters233,27,26787.74%
Institutional Investors11,02,1822.69%
Public & Others313,62,6009.56%
See the full shareholding pattern

Promoter, institutional & public holding for Invictus Oncology.

₹499₹169(excl. taxes)
Buy Financial & Company Filings
What you'll get
  • Incorporation Documents
  • Change in Directors & Designated Partner
  • Board Resolutions
  • Financial Statements & Annual Filings
  • Charge Documents (Summary)

Peer Benchmark

69 peersSame sector + state + ±5y vintage
MetricThis companyCohort medianCohort P75Quartile
Revenue (latest FY)
—
PAT (latest FY)
—
Employees
—
—
—
—
Paid-up capital
—
Compliance Health
63
96
96
Bottom quartile · P1

Top 10 in Pharmaceuticals & Chemicals

by healthView all ›
01
Paid-up
Revenue
A · 96
02
Paid-up
Revenue
A · 96
03
Paid-up
Revenue
A · 96
04
Paid-up
Revenue
A · 96
05
S B Organics Ltd
Telangana · Inc 1988
Paid-up
Revenue
A · 96
06
Ecmas Resins PVT Ltd
Telangana · Inc 1987
Paid-up
Revenue
A · 96
07
Srinivasa Cystine Private Ltd
Telangana · Inc 1983
Paid-up
Revenue
A · 96
08
Paid-up
Revenue
A · 96
09
Paid-up
Revenue
A · 96
10
Paid-up
Revenue
A · 96

Events & timeline

1Filings, charges, board changes
10 Jun 2013
Jasmin appointed as Director

External data sources

7 plannedWhat lands here as ingestion comes online

GSTIN Registrations

Planned
GST portal

Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.

MSME Payment Delays

Planned
MSME-1 form

Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.

Related Party Transactions

Planned
AOC-4 schedule

Counterparty, nature, transaction value. Inter-company loans, sales, royalty.

Credit Ratings

Planned
CRISIL / ICRA / CARE feeds

Long-term + short-term ratings, with rationale on rating actions.

Trademarks

Planned
IP India Trademark Registry

Applied, registered, opposed. Class numbers + status.

Patents

Planned
IP India Patent Registry

Applications and grants. Inventor names + filing dates.

Legal Cases

Planned
eCourts + Indian Kanoon

Ongoing + past litigations the entity is party to.

Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.

FAQs about Invictus Oncology

When was Invictus Oncology incorporated?
Invictus Oncology was incorporated in 2011. Its CIN is U24232DL2011PTC217394 and it is registered with the relevant Registrar of Companies.
Where is Invictus Oncology located?
Invictus Oncology is headquartered in Delhi.
What sector does Invictus Oncology operate in?
Invictus Oncology operates in the Pharmaceuticals & Chemicals sector (NIC code 24232), classified as Indian Non-Govt Company.
Who are the directors of Invictus Oncology?
Director details for Invictus Oncology have not yet been extracted from MGT-7 filings.
What is the paid-up capital of Invictus Oncology?
Invictus Oncology has authorized capital of — and paid-up capital of —.
Does Invictus Oncology have any open charges?
Invictus Oncology has no open MCA-registered charges on record.
What is Invictus Oncology's Compliance Health Score?
RegisterKaro's Compliance Health Score for Invictus Oncology is 30/100 (grade F), based on 9 weighted signals across MCA filings, charges, directors, capital, and overall status. 3 of 9 signals passed.